PDGFRA and gastrointestinal stromal tumor: In a 2016 study on variation analysis in GIST, Schöffski et al41 estimated cost savings associated with withholding empirical imatinib from patients with a PDGFRA D842V variation, which is known to have primary imatinib resistance.